Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
This study seeks to determine the effectiveness of Rucaparib as maintenance therapy for metastatic and recurrent endometrial cancer, after 1-2 prior lines of therapy.
Metastatic Endometrial Cancer
DRUG: Rucaparib|DRUG: Placebo Oral Tablet
Progression Free Survival (PFS), Progression free survival is defined as cycle 1 day 1 (C1D1) till the time of progression as determined by RECIST 1.1 criteria or death., Up to 48 months.
Overall Survival (OS), Overall survival is defined as cycle 1 day 1 (C1D1) till the time of death., Up to 48 months.|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Safety and tolerability analysis of Rucaparib will be summarized by dose and severity as assessed by the Common Toxicity Criteria for Adverse Events (CTCAE) version 5 and relationship to study drug., Up to 48 months.
This is a phase II clinical trial, that administers a maintenance treatment after first line chemotherapy is complete. It is designed to have a 1:1 randomization technique. Half the participants who enter the study will receive the active ingredient, Rucaparib, while the other half will receive a placebo. Treatment will be until progression with follow up until death.